Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2016 from OUS - Department of Cancer Immunology
29 publications found
Deep Sequencing Analysis of Nucleolar Small RNAs: Bioinformatics
Methods Mol Biol, 1455, 243-8
DOI 10.1007/978-1-4939-3792-9_19, PubMed 27576724
Deep Sequencing Analysis of Nucleolar Small RNAs: RNA Isolation and Library Preparation
Methods Mol Biol, 1455, 231-41
DOI 10.1007/978-1-4939-3792-9_18, PubMed 27576723
Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants
Mol Ther, 24 (9), 1675-85
DOI 10.1038/mt.2016.134, PubMed 27377043
Naive Donor NK Cell Repertoires Associated with Less Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
J Immunol, 196 (3), 1400-11
DOI 10.4049/jimmunol.1501434, PubMed 26746188
The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era
Br J Haematol, 175 (1), 102-14
DOI 10.1111/bjh.14201, PubMed 27341313
Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation
Ecancermedicalscience, 10, 691
DOI 10.3332/ecancer.2016.691, PubMed 27994647
Profiling networks of distinct immune-cells in tumors
BMC Bioinformatics, 17 (1), 263
DOI 10.1186/s12859-016-1141-3, PubMed 27377892
Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
Clin Transl Immunology, 5 (11), e109
DOI 10.1038/cti.2016.65, PubMed 27990285
Suppressive effects of tumor cell-derived 5'-deoxy-5'-methylthioadenosine on human T cells
Oncoimmunology, 5 (8), e1184802
DOI 10.1080/2162402X.2016.1184802, PubMed 27622058
Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease
J Hepatol, 66 (1), 116-122
DOI 10.1016/j.jhep.2016.09.002, PubMed 27647428
Myeloid cell leukaemia 1 has a vital role in retinoic acid-mediated protection of Toll-like receptor 9-stimulated B cells from spontaneous and DNA damage-induced apoptosis
Immunology, 149 (1), 62-73
DOI 10.1111/imm.12629, PubMed 27278254
Class I HLA haplotypes form two schools that educate NK cells in different ways
Sci Immunol, 1 (3)
DOI 10.1126/sciimmunol.aag1672, PubMed 27868107
Class I HLA haplotypes form two schools that educate NK cells in different ways
Sci Immunol, 1 (3), eaag1672
DOI 10.1126/sciimmunol.aag1672, PubMed 28783683
T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy
Oncoimmunology, 5 (12), e1249090
DOI 10.1080/2162402X.2016.1249090, PubMed 28123886
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
Oncoimmunology, 5 (11), e1232237
DOI 10.1080/2162402X.2016.1232237, PubMed 27999747
Cognate HLA absence in trans diminishes human NK cell education
J Clin Invest, 126 (10), 3772-3782
DOI 10.1172/JCI86923, PubMed 27571408
Critical Role of CD2 Co-stimulation in Adaptive Natural Killer Cell Responses Revealed in NKG2C-Deficient Humans
Cell Rep, 15 (5), 1088-1099
DOI 10.1016/j.celrep.2016.04.005, PubMed 27117418
Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA
Oncoimmunology, 5 (5), e1138199
DOI 10.1080/2162402X.2016.1138199, PubMed 27467957
Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth
Oncotarget, 7 (46), 75940-75953
DOI 10.18632/oncotarget.12445, PubMed 27713158
Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling
Blood, 129 (6), 759-770
DOI 10.1182/blood-2016-05-718494, PubMed 28011673
Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine
Case Rep Med, 2016, 9639585
DOI 10.1155/2016/9639585, PubMed 27504122
Targeting of cancer neoantigens with donor-derived T cell receptor repertoires
Science, 352 (6291), 1337-41
DOI 10.1126/science.aaf2288, PubMed 27198675
Patterns of constitutively phosphorylated kinases in B cells are associated with disease severity in common variable immunodeficiency
Clin Immunol, 175, 69-74
DOI 10.1016/j.clim.2016.11.014, PubMed 27919819
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
J Vis Exp (116)
DOI 10.3791/54615, PubMed 27842341
VOLIN and KJON-Two novel hyperdiploid myeloma cell lines
Genes Chromosomes Cancer, 55 (11), 890-901
DOI 10.1002/gcc.22388, PubMed 27311012
Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies
J Allergy Clin Immunol Pract, 4 (6), 1089-1100
DOI 10.1016/j.jaip.2016.08.004, PubMed 27836058
PI3-kinase mutation linked to insulin and growth factor resistance in vivo
J Clin Invest, 126 (4), 1401-12
DOI 10.1172/JCI84005, PubMed 26974159
Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency
Cancer Res, 76 (15), 4347-58
DOI 10.1158/0008-5472.CAN-16-0008, PubMed 27261508
Frizzled2 signaling regulates growth of high-risk neuroblastomas by interfering with β-catenin-dependent and β-catenin-independent signaling pathways
Oncotarget, 7 (29), 46187-46202
DOI 10.18632/oncotarget.10070, PubMed 27323822